Trial Profile
A multicenter, randomized phase II study of bortezomib and dexamethasone as induction treatment followed by high dose melphalan (HDM) and autologous stem cell transplantation (SCT) in patients with de novo amyloid light chain (AL) amyloidosis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Autologous stem cell therapy; Dexamethasone
- Indications Amyloidosis
- Focus Therapeutic Use
- Acronyms HOVON 104; HOVON104AL-Amyloidosis
- 15 Jun 2023 Long term follow-up result data presented at the 28th Congress of the European Haematology Association.
- 16 Mar 2022 Status changed from active, no longer recruiting to completed.
- 18 Jun 2021 This trial has been completed in Belgium, according to European Clinical Trials Database.